[HTML][HTML] Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the …
JL Pujol, A Lavole, E Quoix, O Molinier, PJ Souquet… - Annals of …, 2015 - Elsevier
ABSTRACT IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after
chemotherapy induction did not improve outcomes in extensive SCLC patients. Background …
chemotherapy induction did not improve outcomes in extensive SCLC patients. Background …
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 …
JL Pujol, A Lavole, E Quoix, O Molinier… - Annals of …, 2015 - hal.umontpellier.fr
BACKGROUND: This randomized phase II-III trial sought to evaluate the efficacy and safety
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
[PDF][PDF] Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT …
JL Pujol, A Lavole, E Quoix, O Molinier, PJ Souquet… - Annals of Oncology, 2015 - ifct.fr
Background: This randomized phase II–III trial sought to evaluate the efficacy and safety of
adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 …
JL Pujol, A Lavole, E Quoix, O Molinier… - Annals of Oncology …, 2015 - europepmc.org
BACKGROUND: This randomized phase II-III trial sought to evaluate the efficacy and safety
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
[引用][C] Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT …
JL PUJOL, A LAVOLE, E QUOIX, O MOLINIER… - Annals of …, 2015 - jglobal.jst.go.jp
Randomized phase II-III study of bevacizumab in combination with chemotherapy in
previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial …
previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial …
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 …
JL Pujol, A Lavole, E Quoix… - Annals of oncology …, 2015 - pubmed.ncbi.nlm.nih.gov
Background This randomized phase II-III trial sought to evaluate the efficacy and safety of
adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 …
JL Pujol, A Lavole, E Quoix, O Molinier, PJ Souquet… - Annals of …, 2015 - hal.science
BACKGROUND: This randomized phase II-III trial sought to evaluate the efficacy and safety
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell …
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 …
JL Pujol, A Lavole, E Quoix, O Molinier… - Annals of …, 2015 - annalsofoncology.org
ABSTRACT IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after
chemotherapy induction did not improve outcomes in extensive SCLC patients. Background …
chemotherapy induction did not improve outcomes in extensive SCLC patients. Background …